Anipamil is primarily used in cardiovascular research due to its ability to act as a calcium channel blocker. It is particularly studied for its potential to manage hypertension by inhibiting the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Additionally, its long-lasting effects make it a subject of interest in developing sustained-release formulations for treating chronic cardiovascular conditions. Researchers also explore its role in protecting cardiac tissues from ischemic damage, making it relevant in studies related to heart attack prevention and recovery.